Fighting antibiotic resistance through nanodrugs: Success of the European project CYCLON HIT at Université Paris-Saclay and at CNRS
Since March 2014, Ruxandra GREF, Research Director at the CNRS, head of the group "Nanoparticles type" cage "in the fight against severe diseases" at ISMO (Institute of Molecular Sciences at Orsay) is coordinating the ITN Marie-Curie project for excellence CYCLON HIT (ITN FP7-PEOPLE-Project No. 608407), on the theme of "Nanocarriers for the delivery of antimicrobial agents to fight resistance mechanisms".
The world-wide spread of antibiotic-resistant microorganisms can be viewed as an ecological consequence of the systematic use of antimicrobial agents. Resistant bacteria prevail in healthcare environments where antibiotic selective pressure is intensive.
Novel therapeutic approaches are urgently required to deliver the well-documented existing drugs to:
- protect them toward degradation
- increase their bioavailability
- reduce toxic side effects
- increase patient compliance and
- reduce treatment duration and related costs.
In this sense, nanocarriers based on cyclodextrins (CDs) are particularly appealing for the delivery of antibiotics, an approach of main interest for tuberculosis (TB), infections related to Salmonella typhimurium, Staphyloccocus aureus and for species most frequently implicated in hospital infections such as enteric gram-negative rods. The CycloN Hit project takes advantage of the high level interdisciplinary expertise of the partners to efficiently encapsulate and protect antibiotics in CD-based nanocarriers to combat resistant bacteria. This will be accomplished through research training of 11 Early Stage and 5 Experienced Researchers who will gather expertise of 11 Full and 6 associated partners. The final goal is to bring to the preclinical studies an antibiotic formulation for the treatment of TB and more tailored alternative therapeutic approaches for other resistant microorganisms.
CYCLON HIT gathers multidisciplinary expertise in chemistry, nanotechnology, in vitro/in vivo evaluation and scale up.
In October 2015, an international conference gathering more than 300 participants has been organized in Paris, in Pasteur Institute, in the frame of the CYCLON HIT project.
In orther to go further:
CYCLON HIT project: http://itn-cyclonhit.eu/